These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21898393)

  • 1. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
    Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
    Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
    Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
    Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
    Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
    Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy.
    Zong J; Wang C; Liu B; Liu M; Cao Y; Sun X; Yao Y; Sun G
    Oncol Rep; 2013 Jul; 30(1):407-12. PubMed ID: 23660931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
    Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EDA-E7 Activated DCs Induces Cytotoxic T Lymphocyte Immune Responses against HPV Expressing Cervical Cancer in Human Setting.
    Feng J; Liu Y; Zhuang N; Chai Z; Liu L; Qian C; Li J; Shan J
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
    Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
    Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
    Decrausaz L; Domingos-Pereira S; Duc M; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
    Int J Cancer; 2011 Aug; 129(3):762-72. PubMed ID: 21384340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.